Buscar
Kiniksa Pharmaceuticals International PLC
KNSAAñadir a la lista de seguimiento
79.150USD
+15.615+24.58%
Cierre 07-28 16:00（ET）Cotizaciones retrasadas 15 min
6.04BCap. mercado
81.35P/E TTM
Más Datos de Kiniksa Pharmaceuticals International PLC Compañía
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Información de Kiniksa Pharmaceuticals International PLC
Símbolo de cotizaciónKNSA
Nombre de la empresaKiniksa Pharmaceuticals International PLC
Fecha de salida a bolsaMay 24, 2018
Director ejecutivoPatel (Sanjiv K)
Número de empleados315
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 24
Dirección23 Old Bond Street, Floor 3
CiudadLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalWIS 4PZ
Teléfono
Sitio Webhttps://www.kiniksa.com/
Símbolo de cotizaciónKNSA
Fecha de salida a bolsaMay 24, 2018
Director ejecutivoPatel (Sanjiv K)
Ejecutivos de Kiniksa Pharmaceuticals International PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
87.31K
+3.21%
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
66.21K
+74.28%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
65.62K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
21.96K
+12.75%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
16.15K
+25.18%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
15.35K
+18.24%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Independent Director
Independent Director
15.35K
+18.24%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
14.84K
-84.54%
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Director
Independent Director
12.55K
+25.29%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
221.59K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
87.31K
+3.21%
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
66.21K
+74.28%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
65.62K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
21.96K
+12.75%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
16.15K
+25.18%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Kiniksa Pharmaceuticals International PLC?
Los cinco principales accionistas de Kiniksa Pharmaceuticals International PLC son: Mr. Sanjiv K. (Sanj) Patel
¿Cuántas instituciones poseen acciones de Kiniksa Pharmaceuticals International PLC (KNSA)?
A fecha de 2026Q1, 483 instituciones poseen acciones de Kiniksa Pharmaceuticals International PLC, con un valor de mercado combinado de aproximadamente 51.67M, lo que representa el 111.58% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 2211552.00.